Naujienos

• BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies
  12.01.2021 / 12:30 - GlobeNewswire
•  
• INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium
  11.01.2021 / 23:03 - GlobeNewswire
•  
• US shares rise at open as Trump eyes smooth transition
  08.01.2021 / 15:30 - TeleTrader
•  
• BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
  09.12.2020 / 15:00 - GlobeNewswire
•  
• Congenica Appoints Dr. Muthu Meyyappan as Chief Commercial Officer
  01.12.2020 / 08:00 - GlobeNewswire
•  
• MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
  30.11.2020 / 13:30 - GlobeNewswire
•  
• Inivata Appoints Dr. Alan Schafer as Chief Technology Officer
  16.11.2020 / 13:00 - GlobeNewswire
•  
• XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement
  11.11.2020 / 13:30 - GlobeNewswire
•  
• Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
  09.11.2020 / 14:00 - GlobeNewswire
•  
• Merus Announces Financial Results for the Third Quarter and Provides Business Update
  05.11.2020 / 22:10 - GlobeNewswire
•  
• Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
  05.11.2020 / 22:06 - GlobeNewswire
•  
• MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
  04.11.2020 / 22:01 - GlobeNewswire
•  
• Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer
  29.10.2020 / 12:30 - GlobeNewswire
•  
• BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
  21.10.2020 / 12:30 - GlobeNewswire
•  
• Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer
  06.10.2020 / 13:30 - GlobeNewswire